vs
Apellis Pharmaceuticals, Inc.（APLS）与InterDigital, Inc.（IDCC）财务数据对比。点击上方公司名可切换其他公司
InterDigital, Inc.的季度营收约是Apellis Pharmaceuticals, Inc.的1.0倍（$205.4M vs $199.9M），InterDigital, Inc.净利率更高（36.7% vs -29.5%，领先66.1%），InterDigital, Inc.同比增速更快（-2.4% vs -5.9%），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.1%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
InterDigital, Inc.是一家美国科技研发企业，成立于1972年，于纳斯达克挂牌上市，为标普600指数成分股，面向全球市场为移动设备、通信网络及相关服务领域提供无线与视频技术解决方案，在相关技术研发领域拥有深厚积累。
APLS vs IDCC — 直观对比
营收规模更大
IDCC
是对方的1.0倍
$199.9M
营收增速更快
IDCC
高出3.5%
-5.9%
净利率更高
IDCC
高出66.1%
-29.5%
两年增速更快
APLS
近两年复合增速
-4.1%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $205.4M |
| 净利润 | $-59.0M | $75.3M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 40.0% |
| 净利率 | -29.5% | 36.7% |
| 营收同比 | -5.9% | -2.4% |
| 净利润同比 | -62.2% | -34.8% |
| 每股收益（稀释后） | $-0.40 | $2.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSIDCC
| Q1 26 | — | $205.4M | ||
| Q4 25 | $199.9M | $158.2M | ||
| Q3 25 | $458.6M | $164.7M | ||
| Q2 25 | $178.5M | $300.6M | ||
| Q1 25 | $166.8M | $210.5M | ||
| Q4 24 | $212.5M | $252.8M | ||
| Q3 24 | $196.8M | $128.7M | ||
| Q2 24 | $199.7M | $223.5M |
净利润APLSIDCC
| Q1 26 | — | $75.3M | ||
| Q4 25 | $-59.0M | $43.0M | ||
| Q3 25 | $215.7M | $67.5M | ||
| Q2 25 | $-42.2M | $180.6M | ||
| Q1 25 | $-92.2M | $115.6M | ||
| Q4 24 | $-36.4M | $133.1M | ||
| Q3 24 | $-57.4M | $34.2M | ||
| Q2 24 | $-37.7M | $109.7M |
营业利润率APLSIDCC
| Q1 26 | — | 40.0% | ||
| Q4 25 | -25.6% | 30.2% | ||
| Q3 25 | 48.7% | 46.0% | ||
| Q2 25 | -18.6% | 68.3% | ||
| Q1 25 | -50.0% | 62.6% | ||
| Q4 24 | -12.3% | 64.3% | ||
| Q3 24 | -24.0% | 30.6% | ||
| Q2 24 | -14.7% | 59.9% |
净利率APLSIDCC
| Q1 26 | — | 36.7% | ||
| Q4 25 | -29.5% | 27.2% | ||
| Q3 25 | 47.0% | 41.0% | ||
| Q2 25 | -23.6% | 60.1% | ||
| Q1 25 | -55.3% | 54.9% | ||
| Q4 24 | -17.1% | 52.7% | ||
| Q3 24 | -29.2% | 26.6% | ||
| Q2 24 | -18.9% | 49.1% |
每股收益（稀释后）APLSIDCC
| Q1 26 | — | $2.14 | ||
| Q4 25 | $-0.40 | $1.07 | ||
| Q3 25 | $1.67 | $1.93 | ||
| Q2 25 | $-0.33 | $5.35 | ||
| Q1 25 | $-0.74 | $3.45 | ||
| Q4 24 | $-0.30 | $4.12 | ||
| Q3 24 | $-0.46 | $1.14 | ||
| Q2 24 | $-0.30 | $3.93 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | — |
| 总债务越低越好 | — | $377.8M |
| 股东权益账面价值 | $370.1M | $1.1B |
| 总资产 | $1.1B | $2.1B |
| 负债/权益比越低杠杆越低 | — | 0.34× |
8季度趋势，按日历期对齐
现金及短期投资APLSIDCC
| Q1 26 | — | — | ||
| Q4 25 | $466.2M | $1.2B | ||
| Q3 25 | $479.2M | $1.3B | ||
| Q2 25 | $370.0M | $937.0M | ||
| Q1 25 | $358.4M | $883.3M | ||
| Q4 24 | $411.3M | $958.2M | ||
| Q3 24 | $396.9M | $813.2M | ||
| Q2 24 | $360.1M | $760.3M |
总债务APLSIDCC
| Q1 26 | — | $377.8M | ||
| Q4 25 | — | $16.3M | ||
| Q3 25 | — | $17.1M | ||
| Q2 25 | — | $16.6M | ||
| Q1 25 | — | $16.0M | ||
| Q4 24 | — | $15.4M | ||
| Q3 24 | — | $18.3M | ||
| Q2 24 | — | $17.7M |
股东权益APLSIDCC
| Q1 26 | — | $1.1B | ||
| Q4 25 | $370.1M | $1.1B | ||
| Q3 25 | $401.2M | $1.1B | ||
| Q2 25 | $156.3M | $1.1B | ||
| Q1 25 | $164.2M | $936.9M | ||
| Q4 24 | $228.5M | $857.2M | ||
| Q3 24 | $237.1M | $722.5M | ||
| Q2 24 | $264.3M | $696.8M |
总资产APLSIDCC
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.1B | $2.1B | ||
| Q2 25 | $821.4M | $2.0B | ||
| Q1 25 | $807.3M | $1.9B | ||
| Q4 24 | $885.1M | $1.8B | ||
| Q3 24 | $901.9M | $1.7B | ||
| Q2 24 | $904.5M | $1.6B |
负债/权益比APLSIDCC
| Q1 26 | — | 0.34× | ||
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | 0.02× | ||
| Q4 24 | — | 0.02× | ||
| Q3 24 | — | 0.03× | ||
| Q2 24 | — | 0.03× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | — |
| 自由现金流率自由现金流/营收 | -7.1% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | — |
8季度趋势，按日历期对齐
经营现金流APLSIDCC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $544.5M | ||
| Q3 25 | $108.5M | $395.9M | ||
| Q2 25 | $4.4M | $105.1M | ||
| Q1 25 | $-53.4M | $-20.0M | ||
| Q4 24 | $19.4M | $271.5M | ||
| Q3 24 | $34.1M | $77.6M | ||
| Q2 24 | $-8.3M | $-48.9M |
自由现金流APLSIDCC
| Q1 26 | — | — | ||
| Q4 25 | $-14.3M | $528.6M | ||
| Q3 25 | $108.3M | $395.3M | ||
| Q2 25 | $4.4M | $104.5M | ||
| Q1 25 | $-53.4M | $-34.5M | ||
| Q4 24 | $19.3M | $265.7M | ||
| Q3 24 | — | $76.7M | ||
| Q2 24 | $-8.4M | $-49.5M |
自由现金流率APLSIDCC
| Q1 26 | — | — | ||
| Q4 25 | -7.1% | 334.0% | ||
| Q3 25 | 23.6% | 240.1% | ||
| Q2 25 | 2.5% | 34.8% | ||
| Q1 25 | -32.0% | -16.4% | ||
| Q4 24 | 9.1% | 105.1% | ||
| Q3 24 | — | 59.6% | ||
| Q2 24 | -4.2% | -22.1% |
资本支出强度APLSIDCC
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 10.0% | ||
| Q3 25 | 0.0% | 0.4% | ||
| Q2 25 | 0.0% | 0.2% | ||
| Q1 25 | 0.0% | 6.9% | ||
| Q4 24 | 0.0% | 2.3% | ||
| Q3 24 | 0.0% | 0.7% | ||
| Q2 24 | 0.0% | 0.3% |
现金转化率APLSIDCC
| Q1 26 | — | — | ||
| Q4 25 | — | 12.67× | ||
| Q3 25 | 0.50× | 5.87× | ||
| Q2 25 | — | 0.58× | ||
| Q1 25 | — | -0.17× | ||
| Q4 24 | — | 2.04× | ||
| Q3 24 | — | 2.27× | ||
| Q2 24 | — | -0.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
IDCC
暂无分部数据
